Author: admin

Company’s new benchtop system promises a clearer view of proteins following validation at a leading aging research institute. When Seattle-based life sciences company Nautilus Biotechnology stepped onto the stage at US HUPO 2026 in St Louis, the announcement was technical by design. But the implications reach far beyond the conference hall. The company unveiled Voyager, a new proteomics platform that aims to make one of biology’s most complex layers of proteins more readable, repeatable and accessible [1]. Where the difference between healthy aging and disease often lies in subtle molecular shifts, that clarity could matter more than almost any other…

Credit: magicmine/Getty Images For the first time ever, a stem cell therapy has been used to treat spina bifida in a fetus during pregnancy. Results from a Phase I clinical trial, published today in The Lancet, reveal that the treatment is safe and shows early signs of improving mobility and overall health after birth in six children with spina bifida treated using this novel approach.   “By intervening at early stages of development, this approach has the potential to alter lifelong health trajectories, reducing the burden of chronic disability and minimizing the long-term social and economic impact of these conditions,” write…

Credit: wildpixel/Getty Images Researchers at the University of Osaka report that chronic liver congestion (congestive hepatopathy) drives severe liver disease through a pressure-sensitive signaling pathway in liver sinusoidal endothelial cells (LSECs), and have identified molecular targets that may help prevent fibrosis, portal hypertension, and liver cancer. The study, published in Gastroenterology, details how increased venous pressure in the liver activates the integrin αV–YAP–CTGF axis in LSECs and promotes fibrogenesis and tumorigenesis in congestive hepatopathy. Hepatic congestion is a result of a significant and persistent increase in hepatic venous pressure caused by congenital heart disease, right-sided heart failure, Budd-Chiari syndrome, and…

Single-cell chromatin map across 21 tissues reveals coordinated, sex-specific remodeling with age – and hints at systemic drivers. Aging is often described as diffuse – a slow accumulation of molecular wear, cellular drift and systemic fragility. A new study in Science attempts something more precise: to chart, at single-cell resolution, how chromatin accessibility changes across the mammalian body over time, and whether those changes follow discernible patterns rather than stochastic decay. Drawing on more than ten million nuclei profiled across 21 tissues and multiple ages in male and female mice, the researchers constructed what they describe as an organism-wide epigenomic…

Credit: selvanegra/ Getty Images A study completed by PrecisionLife and Ovation.io has uncovered genetic biomarkers that predict whether someone is likely to have a good or a poor response to treatment with glucagon-like peptide-1 receptor agonist (GLP-1) therapies. A range of GLP-1 drugs have been used for treatment of type 2 diabetes for the last 20 years and more recently for treatment of obesity, as these therapies reduce blood glucose and induce weight loss. However, approximately 50% of patients stop taking these drugs within a year of being prescribed them and patient responses to these drugs are known to be…

Stanford-led THRIVE coalition secures up to $34.5m from ARPA-H to build FDA-grade intrinsic capacity score predicting 20-year outcomes. The Advanced Research Projects Agency for Health continues to place deliberate bets on the infrastructure of aging science. In its latest move under the PROSPR program, a Stanford-led coalition has secured up to $34.5 million to develop what it describes as the first FDA-grade Intrinsic Capacity score – a composite measure designed to predict long-term health outcomes including mortality, multimorbidity, hospitalization and loss of functional ability up to 20 years in advance. The initiative, known as THRIVE – Transforming Health: Reclaiming Intrinsic…

Credit; fizkes / iStock / Getty Images Plus A sweeping new study in Science from researchers at The Rockefeller University reframes aging as a coordinated, body-wide process, one that appears to be driven by shared molecular programs rather than isolated tissue decline. Using single-cell chromatin profiling across 21 tissues in mice, the team generated what may be the most comprehensive atlas to date of how aging reshapes cellular identity and abundance throughout the mammalian body. Their findings suggest that aging is not simply gradual wear-and-tear but instead a regulated and partially synchronized biological process, one that may be more druggable…

Alexey Strygin on billionaire mortality, selection bias and what the funding gap reveals about aging research. Imagine you’ve finally joined the ranks of the ultra-wealthy. The world’s best doctors are on call, your schedule is optimized, your diet calibrated, your biomarkers monitored. If money can buy anything, surely it can buy time. Or can it? With access to elite healthcare, personal trainers and experimental therapies, one might expect billionaires to meaningfully outlive the rest of us. The question is simple: do they? To explore this, I examined deaths among billionaires between 2015 and 2025, compiling 389 cases representing approximately $2.2…

AGBT meeting [LeMieux] As the AGBT meeting came to a close, Julianna LeMieux, PhD, Deputy Editor in Chief, chatted with Kevin Davies, PhD, GEN‘s Editorial Director, about some of the biggest news from the meeting. The two discuss the announcement made by Vizgen, including a focus on spatial and organoids, the TruPath Genome product (formerly Constellation mapped reads) from Illumina, Bruker’s spatial launches of CellScape and PaintScape, 10x Genomics’ dated chocolate bars, Cellanome’s technology, and more. If you missed our video discussion on AGBT day one, view it here. Don’t miss Julianna LeMieux’s GEN Live on March 2. We deliver a full…

Credit: David Petrus Ibars / iStock / Getty Images Plus Novo Nordisk and Vivtex have announced a partnership focused on developing a new crop of oral biologics for obesity, diabetes, and associated comorbidities. The partnership pairs Novo Nordisk’s expertise in peptide and protein therapeutics with Vivtex’s proprietary gastrointestinal screening and formulation platform.  Under the terms of the agreement, Vivtex will license select oral drug-delivery technologies to Novo Nordisk. In return, Vivtex is eligible to receive upfront consideration, research funding and milestone payments totalling up to $2 billion and tiered royalties on future product sales as part of the deal. Following…